Pharmacological inhibition of SMYD2 protects against cisplatin-induced renal fibrosis and inflammation

Pharmacological inhibition of SMYD2 protects against cisplatin-induced renal fibrosis and inflammation

SET and MYND domain protein 2 (SMYD2) can methylate histone H3 at lysine36 (H3K36) and some non-histone substrates to play a role in tumorigenesis. However, It is unclear how SMYD2 contributes to chronic kidney disease (CKD). Here, AZ505 or LLY507, which could inhibit SMYD2, were used in cisplatin-i...

Full description

Bibliographic Details
Main Authors: Min Chen, Siyang Zuo, Siyu Chen, Xia Li, Tian Zhang, Dan Yang, Xue Zou, Yuan Yang, Hehua Long, Rui Peng, Huixiong Yuan, Bing Guo, Lirong Liu
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Journal of Pharmacological Sciences
Subjects:
SET and MYND domain containing 2
Chronic kidney disease
Renal fibrosis
Epithelial-mesenchymal transdifferentiation
Extracellular matrix
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861323000415

Internet

http://www.sciencedirect.com/science/article/pii/S1347861323000415

Similar Items